4 transcripts
DVAX
Earnings call transcript
NASDAQ
2024 Q2
6 Aug 24
to be assessed in the Z-1018 trial. Can you give us some sense of what you hope to see? What would you consider encouraging that will prompt further investment
DVAX
Earnings call transcript
NASDAQ
2024 Q1
8 May 24
.
In addition to this continued execution and bolstered by our strong financial position, we continue to assess opportunities to grow beyond our
DVAX
Earnings call transcript
NASDAQ
2023 Q4
22 Feb 24
-mediated immunity assessments in the plague Phase II? And do you think those might be important. Any thoughts on that?
I'll take the first one
DVAX
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
and they support the continued development of Z-1018.
In the second half of 2023, we plan to assess the regulatory pathway with the FDA to support
- Prev
- 1
- Next